Efficacy of brolucizumab and ranibizumab in diabetic macular edema and neovascular age-related macular degeneration: insights from a case series
Abstract
Background: The effectiveness of various anti-vascular endothelial growth factors in treating patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) in Bangladesh lacks comprehensive information.
Objective: We evaluated the efficacy of brolucizumab and ranibizumab and assessed the incidence of drug-related adverse events in nAMD and DME patients of Bangladesh.
Methods: In this retrospective case series, 20 patients who had received either intravitreal brolucizumab (n = 10) or ranibizumab (n = 10) were included. Demographic and clinical characteristics, data on best-corrected visual acuity (BCVA), and optical coherence tomography (OCT) measurements, including macular volume (MV) and central subfield retinal thickness (CSRT), were recorded for each patient at baseline and follow-up visits. In addition, brolucizumab was compared with ranibizumab in terms of above mentioned parameters.
Results: Both brolucizumab and ranibizumab induced changes in patient parameters, including BCVA, OCT measurements, and MV, relative to baseline values. At the 12-week follow-up, neither drug demonstrated statistically significant superiority over the other (P > 0.05 in all cases). However, over the course of treatment, the mean BCVA showed a significant improvement following the initiation of brolucizumab therapy (P = 0.042). In terms of OCT findings, the mean CSRT significantly decreased from 508.5 ± 101.1 µm at baseline to 241 ± 40.4 µm at week 12,…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 20 participants or records.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.